Abstract:Despite a steady decline in the incidence in recent decades, gastric cancer remains one of the most frequent causes of death from cancer in the world. By the time of diagnosis the tumor process is locally advanced or generalized in nearly 70% of patients that reduces the possibility of radical surgical treatment. Peritoneal carcinomatosis is a one of the main causes of treatment failure. There patients need complex treatment with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) to improve the quality and duration of life. Today in Russia, surgeries with IHIC are performed in a very limited number of oncology hospitals, thus there is no unified approach to the perioperative management of these patients. Design: Since November 2010 in our institution we started a prospective clinical study of the use of intraoperative hyperthermic intraperitoneal chemotherapy in patients with locally advanced or metastatic gastric cancer. Materials and methods: The study included 30 patients (18 men and 12 women) who underwent transabdominal gastrectomy with extended lymphadenectomy D2, supplemented principled cholecystectomy and oophorectomy (in women). Mean age was 48.5 ± 5.3 years. Technique involved the use of regional anesthesia com- ponent and inhalation anesthetic sevoflurane. Preoperative preparation included enteral nutrition (based on 25-30 kcal/ kg/day), liver protection (intravenous remaxol infusion of 500 ml/day for 3 days prior to surgery), antisecretory and antifermental therapy (omeprazole 40 mg/day, 100 mg octreotide for 2 h before surgey, aprotinin sulfate 30000 after induction of anesthesia), antioxidant and immunomodulatory therapy (galavit, cytoflavin, ceruloplasmin vitamin C), anticoagulant prophylaxis (enoxaparin sodium 40 mg on the evening before surgery). Results: Analysis of the world and our own clinical experience with intraoperative hyperthermic intraperitoneal chemotherapy in a comprehensive plan of treatment of patients with gastric cancer showed that the this aggressive, but highly effective technique can be requires not only careful patient selection according to the criteria, but also the use of special methods to protective therapy at all stages of the surgical treatment. Application of pathogenetic ways of protection from thermal injury, timely control and correction of homeostasis caused by the toxic effects of chemotherapy and burn peritoneum, early enteral nutrition and the use of organ-therapy reduce the risk of complications and achieve better results of treatment in cancer patients.

Current Influence of Intraperitoneal Cisplatin Chemotherapy During Operation on Patients with Gynecologic Malignant Tumor

Preoperative Intraperitoneal Chemotherapy for Patients with Gastric Cancer

Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia to cure advanced ovarian cancer

Intraperitoneal Administration of Cisplatin Plus Bevacizumab for the Management of Malignant Ascites in Ovarian Epithelial Cancer: Results of A Phase Iii Clinical Trial

Clinical Study of Cisplatin Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Docetaxel, 5-Flourouracil and Leucovorin Intravenous Chemotherapy for the Treatment of Advanced-Stage Gastric Carcinoma.

Combined Surgery and Extensive Intraoperative Peritoneal Lavage vs Surgery Alone for Treatment of Locally Advanced Gastric Cancer: The SEIPLUS Randomized Clinical Trial.

Introducing Hyperthermic Intraperitoneal Chemotherapy into Gynecological Oncology Practice - Feasibility and Safety Considerations: Single-Center Experience

Developing a Highly Stable PLGA-mPEG Nanoparticle Loaded with Cisplatin for Chemotherapy of Ovarian Cancer.

Clinical Effect of Early Postoperation Adjuvant Intraperitoneal Chemotherapy of Locally Advanced Gastrie Cancer

A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy

Intraperitoneal chemotherapy combined with intravenous chemotherapy after operation in the ovarian epithelial cancer

Intraperitoneal Irrigation Chemotherapy with Lobaplatin in Locally Advanced Gastric Cancer: A Special Type of Abdominal Chemotherapy

Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.

Evaluation of the Effect of Different Inhalation Agents on Ovaries with Hyperthermic Intraperitoneal Chemotherapy: An Experimental Study

Intra-operative Hyperthermic Intraperitoneal Chemotherapy for Prevention and Treatment of Peritoneal Metastases from Gastric Cancer: a Narrative Review

THE EFFECTS OF INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY COMBINING WITH HIGH-FREQUENCY DIATHERMIC THERAPY IN POSTOPERATIVE GASTROINTES-TINAL CANCER

[Anaesthesia and intensive care during intraoperative intraperitoneal hyperthermic chemotherapy in patients with gastric cancer (literature review and own clinical experience)]

Phase II Trial of Prophylactic Hyperthermic Intraperitoneal Chemotherapy in Patients with Locally Advanced Gastric Cancer after Curative Surgery

Intraperitoneal Perfusion Chemotherapy And Whole Abdominal Hyperthermia Using External Radiofrequency Following Radical D2 Resection For Treatment Of Advanced Gastric Cancer

Feasibility and safety of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: a single-center experience

Cisplatin Combined with Hyperthermia Kills HepG2 Cells in Intraoperative Blood Salvage but Preserves the Function of Erythrocytes.